• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InMode Ltd.

    5/19/25 7:00:11 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email
    6-K 1 zk2533216.htm 6-K


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13In a-16 OR 15d-16 OF
    THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025



    INMODE LTD.


    (Exact name of registrant as specified in its charter)

    Tavor Building, Sha’ar Yokneam
    P.O. Box 533
    Yokneam 2069206 Israel
     
    (Address of Principal Executive Offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    Form 20-F  ☒             Form 40-F ☐

    Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

    Yes ☐             No ☒


    Further to its Current Report on Form 6-K, dated April 3, 2025, InMode Ltd. (the “Company”) announces that on May 15, 2025, the Company held its Annual General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company's shareholders voted on the following 3 proposals:

    (1)
    (a) To re-elect Mr. Moshe Mizrahy to serve as a Class III director of the Company, and to hold office until the annual general meeting of shareholders to be held in 2028 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.

    (b) To re-elect Michael Kreindel to serve as a Class III director of the Company, and to hold office until the annual general meeting of shareholders to be held in 2028 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.

    (2)
    To approve the re-appointment of Kesselman & Kesselman, Certified Public Accounts (Isr.), a member of PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal year ending December 31, 2025, and its service until the annual general meeting of shareholders to be held in 2026.
     
    (3)
    To approve the grant of a total of 7,000 restricted share units under the Company’s 2018 Incentive Plan to each of the following directors: Dr. Hadar Ron (2,000 RSUs), Dr. Michael Anghel (2,000 RSUs) and Mr. Nadav Kenneth (3,000 RSUs), half of which shall vest on February 15, 2026, and the remaining half shall of which shall vest on February 15, 2027, subject to their continued service on the date of vesting.

    Each of the proposals was described in more detail in the Company’s proxy statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K (a “Form 6-K”) furnished to the Securities and Exchange Commission (the “SEC”) on April 3, 2025. On April 11, 2025, the record date for the Meeting (the “Record Date”), there were 63,209,152 ordinary shares issued and outstanding. At the Meeting, there were present in person or by proxy, 33,305,683 of the Company’s outstanding ordinary shares, representing approximately 52.69% of the Company’s ordinary shares issued and outstanding as of the Record Date. Under the Company’s Articles of Association, the Meeting was properly convened, and a quorum was present.

    Based on the voting results and the majority requirements for the proposals under the Israeli Companies Law and the Company’s Articles of Association, each of Proposals 1(a), 1(b), 2 and 3 was approved.

    This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933, as amended.


    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    InMode Ltd.
       
     
    By: /s/ Moshe Mizrahy
     
    Moshe Mizrahy
     
    Chief Executive Officer

    Dated May 19, 2025


    Get the next $INMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology

      YOKNEAM, Israel, May 20, 2025 /CNW/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of IgniteRF, an advanced platform offering a comprehensive suite of minimally invasive radiofrequency solutions for the face and body.     IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results

      5/20/25 9:17:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Present at Upcoming Investor Conferences and Events

      YOKNEAM, Israel, May 7, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here. Barclays West Coast Bus Trip Presenters: Yair Malca, Chief Financial Officer Format: In-person investor bus tour at InMode's North American headquarters When: Thurs

      5/7/25 8:30:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    SEC Filings

    See more
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      5/19/25 7:00:11 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/28/25 7:00:06 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/3/25 7:07:38 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:31:18 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:25:40 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by InMode Ltd.

      SC 13G - InMode Ltd. (0001742692) (Subject)

      2/6/24 9:36:39 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InMode downgraded by BTIG Research

      BTIG Research downgraded InMode from Buy to Neutral

      4/29/25 8:06:22 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

      4/28/25 1:56:11 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on InMode with a new price target

      BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

      10/17/24 7:41:34 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Financials

    Live finance-specific insights

    See more
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

      In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares  YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as

      4/28/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M

      Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

      4/14/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care